Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma

Am J Hematol. 2017 Nov;92(11):1267-1268. doi: 10.1002/ajh.24733. Epub 2017 Jun 5.

Authors

Ajay Major¹, Zenggang Pan², Manali Kamdar³

Affiliations

¹ Department of Medicine, Internal Medicine Residency Training Program, University of Colorado School of Medicine, Aurora, Colorado, USA.
² Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado, USA.
³ Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, USA.

PMID: 28370436
DOI: 10.1002/ajh.24733

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Anaplastic Lymphoma Kinase
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Brain Neoplasms* / diagnostic imaging
Brain Neoplasms* / drug therapy
Brain Neoplasms* / metabolism
Brain Neoplasms* / pathology
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Etoposide / administration & dosage
Fatal Outcome
Humans
Lymphoma, Large-Cell, Anaplastic* / diagnostic imaging
Lymphoma, Large-Cell, Anaplastic* / drug therapy
Lymphoma, Large-Cell, Anaplastic* / metabolism
Lymphoma, Large-Cell, Anaplastic* / pathology
Male
Prednisolone / administration & dosage
Receptor Protein-Tyrosine Kinases
Vincristine / administration & dosage

Substances

Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Prednisolone
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases

Supplementary concepts

CHOEP protocol